Table 1. Clinical data of malignant fibrous histiocytomas.
Sample | Sample origin | Patient age/sex | Diagnosis | MFH Subtype | Grade1 | Primary tumour location | Size (cm)2 | Metastasis (months)3 | Status | Follow-up (months)4 |
MFH1 | Rec | 87/M | MFH | Myxofibrosarcoma | 4 | Lower arm | 5 | 48 | DD | 50 |
MFH2x | Rec | 71/M | MFH | Spindle and pleomorphic | 4 | Upper trunk | 19 | 4 | DD | 15 |
MFH4 | Prim | 77/M | MFH | Spindle and pleomorphic | 4 | Upper arm | 15 | MD | DD | 3 |
MFH7 | Prim | 68/M | MFH | Spindle and pleomorphic | 4 | Upper leg | 6 | NM | DOC | 74 |
MFH8 | Met | 76/M | MFH | Spindle and pleomorphic | 4 | Knee5 | 6 | 15 | DD | 27 |
MFH9 | Rec | 57/F | MFH | Spindle and pleomorphic | 4 | Upper leg | 3 | NM | DOC | 346 |
MFH14 | Prim | 60/M | MFH | Spindle and pleomorphic | 4 | Knee | 5.5 | 38 | DD | 82 |
MFH15 | Prim | 45/F | MFH | Pleomorphic with giant cells | 4 | Upper leg | 20 | 6 | DOC | 6 |
MFH16 | Rec | 63/M | MFH | Myxofibrosarcoma | 4 | Upper trunk | NA | NM | DOC | 191 |
MFH18 | Prim | 61/M | MFH | Spindle and pleomorphic | 4 | Lower leg | 18 | 16 | DD | 28 |
MFH19 | Rec | 71/F | MFH | Spindle and pleomorphic | 4 | Upper leg | 5 | NM | NED | 168 |
MFH20 | Met | 66/M | MFH | Spindle and pleomorphic | 4 | Upper leg6 | 18 | 17 | DD | 40 |
MFH21 | Prim | 73/F | MFH | Spindle and pleomorphic | 4 | Upper trunk | 15 | 7 | DD | 21 |
MFH24 | Prim | 92/F | MFH | Spindle and pleomorphic | 4 | Upper leg | 13 | NM | NED | 159 |
MFH25 | Prim | 47/F | MFH | Myxofibrosarcoma | 4 | Upper leg | 20 | NM | NED | 182 |
MFH27 | Rec | 60/M | MFH | Spindle and pleomorphic | 3 | Knee | 7.5 | 34 | DD | 181 |
MFH30 | Prim | 56/M | MFH | Spindle and pleomorphic | 4 | Retroperitoneum | 15 | MD | DD | 3 |
MFH34 | Rec | 79/F | MFH | Spindle and pleomorphic | 3 | Upper trunk | 1.7 | NM | DOC | 80 |
MFH36 | Prim | 75/M | MFH | Myxofibrosarcoma | 4 | Shoulder | 20 | 7 | DD | 14 |
MFH42 | Prim | 71/M | MFH | Pleomorphic with giant cells | 4 | Upper arm | 7.5 | 4 | DD | 22 |
MFH44 | Rec | 80/F | MFH | Spindle and pleomorphic | 4 | Upper leg | 13 | NM | DOC | 15 |
MFH45 | Prim | 69/F | MFH | Spindle and pleomorphic | 4 | Upper arm | 14 | NM | NED | 119 |
MFH46 | Prim | 82/M | MFH | Spindle and pleomorphic | 4 | Upper leg | 11 | NM | NED | 86 |
MFH47 | Prim | 56/M | MFH | Spindle and pleomorphic | 4 | Upper leg | 7 | 7 | DD | 19 |
MFH48 | Prim | 63/M | MFH | Spindle and pleomorphic | 4 | Lower leg | 7 | MD | DD | 100 |
MFH53 | Prim | 69/F | MFH | Pleomorphic with giant cells | 4 | Retroperitoneum | 18 | 5 | DD | 10 |
MFH54 | Prim | 45/M | MFH | Myxofibrosarcoma | 4 | Upper leg | 20 | 6 | DD | 7 |
MFH56 | Prim | 75/F | MFH | Spindle and pleomorphic | 4 | Upper arm | 10 | 9 | NED | 85 |
MFH59 | Prim | 68/M | MFH | Spindle and pleomorphic | 4 | Upper trunk | 10.5 | MD | DD | 7 |
MFH60 | Prim | 58/F | MFH | Pleomorphic | 4 | Upper arm | 11 | 9 | DD | 58 |
MFH61 | Prim | 66/M | MFH | Myxofibrosarcoma | 4 | Upper leg | 9.5 | NM | NED | 74 |
MFH73x | Rec | 82/F | MFH | Spindle cell | 4 | Lower arm | 7 | 14 | DOC | 59 |
MFH76x | Prim | 69/F | MFH | Spindle and pleomorphic | 4 | Lower leg | 10 | 8 | DD | 18 |
Abbreviations: x, xenograft; Rec, recurrence; Prim, primary tumour; Met: metastasis; M, male; F, female; MFH, malignant fibrous histiocytoma; NA, not available; MD, metastasis at diagnosis; NM, no metastasis; DD, dead of disease; DOC, dead of other cause; NED, no evidence of disease;
Grading is based on a four-tiered system used in the Scandinavian Sarcoma Group (SSG);
Largest diameter of the tumour;
Time to first metastasis from diagnosis;
Time to last follow-up from diagnosis;
Metastasis located in the lung;
Metastasis located in the abdominal wall.